IPO - Profile

Summary

We are a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. We use our proprietary platform to develop product candidates that stimulate powerful, targeted immune responses against pathogens and tumor cells.

We design our product candidates to stimulate immune responses that are robust, highly specific, and are differentiated by the magnitude of the T cell populations induced, which exhibit critical functionality and durability. We are focused on applying our platform capabilities and the expertise of More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$17.00 6,500,000 Positive High 53.78%

Offering Team

  • Legal counsel
  • Goodwin Procter LLP
  • Auditors
  • BBD, LLP

Deal Highlights

Deal Tracker

IPO Dates

Filing 29 Apr, 2021

Offer 30 Apr, 2021

Look Ahead

Lock Up Expiry Oct 30, 2021

IPO Terms

Offer Price $17.00
Offer Size 6M

Market Sentiments

Stock Price